NEJM: How effective is BNT162b2 to strengthen the protection of Covid-19 in different age groups?

The initial results of the third dose of (enhanced) BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) in people 60 years of age or older are encouraging.
Israel’s vaccine boosting campaign has gradually expanded to younger people.
They were 5 months ago Received the second dose of vaccination
.

Recently, a research article was published in the top medical journal NEJM.
Researchers extracted data from the Israeli Ministry of Health database from July 30 to October 10, 2021, involving two doses of BNT162b2 received at least 5 months ago.
Of 4,696,865 subjects 16 years of age or older
.

In the main analysis, the researchers compared the diagnosis rate of coronavirus disease (Covid-19) in 2019 between subjects who received booster vaccine at least 12 days ago (boost group) and subjects who did not receive booster vaccine (non-boost group) , Severe illness rate and mortality rate
.

Strengthen the group confirmed infection rate is lower than the unreinforced immunohistochemical about 10 times (five age group across the range of 9.
0 to 17.
2), to strengthen the group to strengthen lower than earlier immunohistochemical 4.
9 to 10.
8 times
.

It can be seen that in all age groups, compared with participants who have not received the booster dose of BNT162b2 vaccine, the rate of confirmed Covid-19 and serious illness in the booster group is much lower
.

Original source:
 
Yinon M.